Risks and benefits of phase 1 clinical trials evaluating new anticancer agents: a case for more innovation
- PMID: 15523076
- DOI: 10.1001/jama.292.17.2150
Risks and benefits of phase 1 clinical trials evaluating new anticancer agents: a case for more innovation
Comment on
-
Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.JAMA. 2004 Nov 3;292(17):2130-40. doi: 10.1001/jama.292.17.2130. JAMA. 2004. PMID: 15523074
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
